TCT 2009 schedule

Jump to navigation Jump to search

Here is the page we will use to coordinate the TV events at TCT 2009.



Click on Date for Detailed Schedule

Monday September 21, 2009

Tuesday September 22, 2009

Wednesday September 23, 2009

Thursday September 24, 2009

Friday September 25, 2009


Monday September 21, 2009

1:05 PM

1:05 PM - 1:15 PM

  • Event: The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
  • Room: 104

1:51 PM

1:51 PM - 2:03 PM

  • Event: The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
  • Room: 104

Return to top

Tuesday September 22, 2009

10:00 AM

10:00 AM - 12:00 PM

  • Event: Oral Abstracts- AMI
  • Room: 125


12:30 PM

12:30 PM - 1:00 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Pieter C. Smits
  • Trial: COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
  • Phone number:


1:00 PM

1:00 PM - 1:30 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Shamir Mehta
  • Trial: CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
  • Phone number:


2:00 PM

2:00 PM - 2:30 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: John Spertus
  • Trial: NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
  • Phone number:


2:30 PM

2:30 PM - 3:00 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Eberhard Grube
  • Trial: BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
  • Phone number:


3:00 PM

3:00 PM - 3:30 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: David Allie
  • Trial: CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
  • Phone number:


3:30 PM

3:30 PM - 4:00 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Douglas Losordo
  • Trial: ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
  • Phone number:


4:00 PM

4:00 PM - 4:30 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Gary Ansel
  • Trial: ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
  • Phone number:


4:30 PM

4:30 PM - 5:00 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Ran Kornowski
  • Trial:
  • Phone number:



Return to top

Wednesday September 23, 2009

8:30 AM

8:30 AM - 9:00 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: William Fearon
  • Confirmed: Yes
  • Trial: FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
  • Phone number:

9:00 AM

9:00 AM - 9:30 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: Lorenz Raber
  • Confirmed: Yes
  • Trial: SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents
  • Phone number:

9:30 AM

9:30 AM - 10:00 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: Volker Klauss
  • Confirmed: Yes
  • Trial: LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
  • Phone number:

10:00 AM

10:00 AM - 10:30 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: Deepak Bhatt
  • Confirmed: Yes
  • Trial: 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention

  • Phone number:

10:30 AM

10:30 AM - 11:00 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: David Cohen
  • Confirmed: Yes
  • Trial: TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI
  • Phone number:

11:00 AM

11:00 AM - 11:30 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: Chris Cannon
  • Confirmed: Yes
  • Trial: PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
  • Phone number:

12:00 PM

12:00 PM - 12:30 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Robert Byrne
  • Confirmed: Yes
  • Trial: ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents
  • Phone number:

12:45 PM

12:45 PM - 12:50 PM

  • Event: Open Issues I: Adjunct Pharmacology. Schedule
  • Room: 130

1:35 PM

1:35 PM - 1:45 PM

  • Event: Open Issues I: Adjunct Pharmacology. Schedule
  • Room: 130

4:00 PM

4:00 PM - 4:45 PM

  • Event: Main Arena I. Plenary Session #7 Personalized Clinical Decision-Making Case Study: The Ischemia vs. Bleeding Controversy
  • Room: Esplanade Ballroom

Return to top

Thursday September 24, 2009

8:46 AM

8:46 AM - 11:11 AM

  • Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 2: Current Choices in Antithrombin Therapy for ACS and PCI
  • Room: 135

11:45 PM

11:45 AM - 11:57 AM

  • Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
  • Room: 135

12:09 PM

12:09 PM - 12:24 PM

  • Event: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
  • Room: 135

12:45 PM

12:45 PM - 1:15 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Cheol Whan Lee
  • Trial: 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
  • Phone number:

1:15 PM

1:15 PM - 1:45 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Flavio Ribichini
  • Trial: CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
  • Phone number:

1:45 PM

1:45 PM - 2:15 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Josef Veselka
  • Trial: STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
  • Phone number:

2:15 PM

2:15 PM - 2:45 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Patrick Ohlmann
  • Trial: MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
  • Phone number:

2:45 PM

2:45 PM - 3:15 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Junbo Ge
  • Trial: NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
  • Phone number:

3:15 PM

3:15 PM - 3:45 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Giulio Guagliumi
  • Trial: OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
  • Phone number:

3:45 PM

3:45 PM - 4:15 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Josep Rodes-Cabau
  • Trial: The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
  • Phone number:

4:15 PM

4:15 PM - 4:45 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Dirk Walter
  • Trial: PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
  • Phone number:

5:02 PM

5:02 PM - 5:14 PM

  • Event: Balancing Safety and Efficacy of Antithrombotic Therapies for PCI and ACS. Antiplatelet Agents, Bleeding, and Ischemia
  • Room: 135

Return to top

Friday September 25, 2009

10:30 AM

10:30 AM - 11:00 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: Simon Redwood
  • Confirmed: Yes
  • Trial: BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
  • Phone number:

11:00 AM

11:00 AM - 11:30 AM

  • Event: Interview
  • Room: East 264
  • Interviewee: Arnold Seto
  • Confirmed: Yes
  • Trial: FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
  • Phone number:

12:30 PM

12:30 PM - 1:00 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Rolf Michels
  • Confirmed: Yes
  • Trial: DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
  • Phone number:

1:00 PM

1:00 PM - 1:30 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Gregg Stone
  • Confirmed: Yes
  • Trial: 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI

  • Phone number:

1:30 PM

1:30 PM - 2:00 PM

  • Event: Interview
  • Room: East 264
  • Interviewee: Henry Krum
  • Confirmed: Yes
  • Trial: SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
  • Phone number:

2:24 PM

2:24 PM - 2:36 PM

  • Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

GPIIb/IIIa Inhibitors in ACS: EARLY ACS

  • Room: EBM and Guidelines Theater, Hall D

2:36 PM

2:36 PM - 3:12 PM

  • Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7

  • Room: EBM and Guidelines Theater, Hall D

3:00 PM

3:00 PM - 3:12 PM

  • Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7

  • Room: EBM and Guidelines Theater, Hall D

3:24 PM

3:24 PM - 3:36 PM

  • Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Ticagrelor in ACS: PLATO

  • Room: EBM and Guidelines Theater, Hall D

3:36 PM

3:36 PM - 3:48 PM

  • Event: Top Interventional Trials of the Last Year: Perspectives from the Experts

Ticagrelor in ACS: PLATO

  • Room: EBM and Guidelines Theater, Hall D

Return to top